Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.59 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973444 | 0.89 | HSD11B1 (0.49) | HSD11B1HSD11B2GPR119 | |
| SCHEMBL16215953 | 0.87 | HSD11B1 (0.64) | HSD11B1HSD11B2 | |
| SCHEMBL3663716 | 0.86 | HSD11B1 (0.69) | HSD11B1HSD11B2 | |
| SCHEMBL975411 | 0.83 | HSD11B1 (0.46) | HSD11B1HSD11B2GPR119 | |
| SCHEMBL975330 | 0.83 | HSD11B1 (0.48) | HSD11B1HSD11B2 | |
| SCHEMBL3662720 | 0.82 | HSD11B1 (0.65) | HSD11B1HSD11B2GPR119 | |
| SCHEMBL3661380 | 0.82 | HSD11B1 (0.65) | HSD11B1HSD11B2GPR119 | |
| SCHEMBL973488 | 0.81 | HSD11B1 (0.47) | HSD11B1HSD11B2GPR119 | |
| SCHEMBL973454 | 0.79 | HDAC1 (0.52) | HSD11B1HSD11B2GPR119 | |
| SCHEMBL27809383 | 0.79 | HSD11B1 (0.54) | HSD11B1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-8530657-B2 | Substituted adamantanes and their therapeutic application | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| EP-2238126-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009112691-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009391-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | BHMT, UGDH, NNMT | HSD11B1 4293/4885HSD11B2 4431/4885GPR119 537/4885 |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | UGDH, HNMT, NNMT | HSD11B1 2913/4885HSD11B2 3024/4885GPR119 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.